CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Alizyme plc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Alizyme plc
Granta Park
Great Abington
Phone: (1223) 896-000p:1223 896-000 Cambridge, ENG  CB1 6GS  United Kingdom Ticker: AZM AZM
Alizyme plc is in administration. The affairs, business and property of Alizyme plc are being managed by Ian Carr and Nigel Morrison, who were appointed Joint Administrators on 27 July 2009.
This company is no longer actively traded on any major stock exchange.
Business Summary
Alizyme plc is a speciality bio-pharmaceutical development company, focused on the therapeutic areas of metabolic disorders, gastrointestinal disorders and cancer supportive care. It is developing and commercialising products for the treatment and management of obesity and type 2 diabetes, of gastrointestinal disorders, involving inflammation, such as ulcerative colitis, and of the gastrointestinal side effects of cancer therapy, such as mucositis. The Company has three late-stage drug candidates, including Cetilistat, COLAL-PRED and ATL-104. Cetilistat is being developed for the treatment of obesity and type 2 diabetes. COLAL-PRED is a gastrointestinal product developed for the treatment of ulcerative colitis. ATL-104 is being developed as an orally administered mouthwash for the treatment of mucositis of the mouth and gastrointestinal tract arising during cancer treatment. In April 2008, the development of renzapride was discontinued following results of the Phase III study.
(Source: ARS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/200812/31/2008Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board Alan G.Goodman 4/23/2009 4/23/2009
Company Secretary NickBlech 9/5/2008 9/5/2008
Research and Development Director, Executive Director RogerHickling 54 12/1/2006 12/1/2006
3 additional Officers and Directors records available in full report.

General Information
Number of Employees: 13 (As of 12/31/2008)
Outstanding Shares: 221,098,686 (As of 2/19/2009)
Shareholders: 4,096
Stock Exchange: SEA
Fax Number: (1223) 896-001


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023